MedTrace Logo

Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus

NCT00017641 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2005-06-24

No results posted yet for this study

Summary

OBJECTIVES:

I. Determine the safety of immune ablation with high-dose cyclophosphamide and anti-thymocyte globulin followed by peripheral blood stem cell support in patients with systemic lupus erythematosus.

Conditions

Interventions

DRUG

anti-thymocyte globulin

DRUG

cyclophosphamide

DRUG

filgrastim

PROCEDURE

CD34+ Peripheral Blood Stem Cell Reinfusion

Sponsors & Collaborators

  • Northwestern Memorial Hospital

    lead OTHER

Principal Investigators

  • Ann Traynor · Northwestern Memorial Hospital

Study Design

Purpose
TREATMENT

Eligibility

Min Age
0 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00017641 on ClinicalTrials.gov